146 results about "Vaccine product" patented technology

The present invention relates to Lawsonia intracellularis vaccines and methods for protecting against and diagnosing L. intracellularis infection. The products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of L. intracellularis, including both a novel isolate of L. intracellularis of European origin and a method of preparing a lyophilized product containing the attenuated European isolate as vaccine product.

The invention relates to a PCV2 (porcine circovirus 2) ELISA (enzyme-linked immuno sorbent assay) antigen detection kit as well as a preparation method and applications thereof, wherein the detection kit comprises an elisa plate of a polyclonal antibody of peridium anti-PCV2-Cap (nucleocapsid) protein, seal liquids, sample diluent, an antigen standard product, a second antibody of a monoclonal antibody of HRP marked anti-PCV2-Cap protein, a concentrated washing liquid, an enzyme substrate solution A, an enzyme substrate solution B and a stop solution, wherein the antigen standard product is purified reconstructed PCV2-Cap protein. The specificity of the kit provided by the invention achieves 100%, and the sensitivity is as high as 4ng/ml, and the kit can be used for swinery PCV2 antigen detection and PCV2 vaccine product quantitative detection.

The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as β-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.

The invention discloses a chicken new castle disease-infectious bronchitis trivalent combined vaccine and a preparation method thereof. The trivalent combined vaccine comprises antigens and a freeze-drying protective agent. The antigens comprise a chicken kidney-type infectious bronchitis virus K136 strain having an accession number of CCTCC-V201320, a chicken breath-type infectious bronchitis virus H120 strain, and a chicken new castle disease virus La Sota strain. A mode of inoculating the K136 strain and the La Sota strain in a homeomorphism manner and inoculating the H120 strain individually is adopted for preparing the antigens. Based on the mode, after culture products are mixed according to a ratio to prepare the antigens, a product of the vaccine is obtained by adding the freeze-drying protective agent. The trivalent combined vaccine can prevent the chicken new castle disease and the chicken infectious bronchitis simultaneously, thus solving effectively a problem that vaccines at present can only provide a part of protection or cannot provide protection for the kidney-type IB, and achieving an objective that one injection can be used for preventing two diseases.

The invention belongs to the field of animal biomedicine engineering, and in particular discloses protein recombinant lactococcus lactis for secretory expression of a core antigen COE of a PEDV (Porcine Epidemic Diarrhea Virus) as well as a preparation method and an application of the protein recombinant lactococcus lactis. The method comprises the following steps: connecting a signal peptide and other sequences onto a gene of the core antigen COE of the PEDV via an overlap extension PCR method by designing multiple primers, connecting the gene to a lactococcus lactis expression vector pNZ8048 and introducing the vector with the gene into a cell of the lactococcus lactis NZ9000 in an electrotransformation manner so as to obtain recombinant bacteria; and inducing the recombinant bacteria with nisin so as to obtain an expression, and directly taking all induced cultures as oral vaccines capable of stimulating mice and inducing strong cellular immune responses. Thus, the protein recombinant lactococcus lactis can serve as a novel oral vaccine product with a good industrial prospect and has a positive effect for reducing harms of the PEDV to pig industry, thereby playing a great practical significance for promoting the healthy development of the pig industry.

The present invention is after-treatment process of deactivated vaccine of attenuated polio strain. The large scale cultured virus liquid is three stage filtered in filtering columns of 06-1.0 micron, 0.45-0.6 micron and 0.22-0.45 micron pore size separately, clarified, ultrafiltered and concentrated, chromatographic column purified and deactivated to obtain semi-finished vaccine product with high purity, good immunogenicity, high safety and stable quality for the requirement of producing the attenuated polio strain. The semi-finished vaccine product can meet the requirement of product and may be used to produce Aabin IPV vaccine with stable quality, high safety and excellent immunogenicity.

The invention discloses an F-gene type attenuated live mumps vaccine and a preparation method and application thereof, relating to an attenuated live mumps vaccine which is prepared in such a way that a separated F-gene type mumps attenuated live seed is inoculated to the human diploid cells (KMB17 strain) and is subjected to subsequent processes and the freezing-drying technology. The vaccine product has good immunogenicity and safety. The invention provides a cryoprotectant which does not contain glutin, thereby ensuring that the attenuated live mumps vaccine has good appearance, low moisture content and good stability.

The invention discloses a method for replicating and proliferating avian influenza viruses in the passage cells which are absorbed and grow in the microcarrier of a bioreactor. The invention is based on the method which uses cells as carrier to proliferate viruses in the bioreactor. The obtained avian influenza viruses and the avian influenza virus vaccine product have uniform quality and stable toxicity. The automatic control of vaccine production can be realized, the problem of large-scale production and application can be solved, the production matrix of the influenza vaccine can be completely changed, the technology that chick embryo is adopted to culture viruses can be changed, the problems caused by chick embryo such as adventitious agent pollution and viral pollution and the interferences caused by heterologous proteins such as chick embryo can be reduced, the purity, safety and immune effect of vaccine can be increased and the method can play an important role in the prevention of avian influenza.

The invention provides a CoxA16 virus strain, named CoxA16 (GX-20K-D virus strain) with CGMCCNo.6350 and including three bases, namely an original seed base, a master seed base and a working seed base; in addition, the CoxA16 virus strain has a nucleotide sequence shown as SEQNo.1. The invention has the following obvious beneficial effects: 1, a virus strain is provided for preparing a human CoxA16 inactivated vaccine and has effective immunogenicity and good growth and replication capacity on cells; 2, a production and preparation method of the human CoxA16 inactivated vaccine which is prepared from KMB17 human diploid cell matrix is provided, and the vaccine product has excellent immunogenicity and safety; and a suspended absorption technical method is provided so as to ensure the effective infection of the CoxA16 inactivated vaccine virus strain on KMB17 cell and excellent growth of the CoxA16 inactivated vaccine virus strain on the matrix.

The invention provides a cell-factory-based measles virus stock solution and a measles-series attenuated live vaccine preparation. A preparation method of the measles virus stock solution includes selecting SPF chick-embryo cells, and adding cell culture fluid to prepare cell suspension liquid, and adding the cell suspension liquid into a cell factory; inoculating the cell factory with working seeds of measles viruses and the cell suspension liquid according to the ratio of the working seeds to the cell suspension liquid being (0.005-0.05):1, and standing and cultivating the cell factory at the temperature of 33+/-1 DEG C for 3-4 days, pouring out archeocyte culture fluid, and replacing with fresh cell growth liquid for continuous cultivation; during cytopathy, collecting single measles virus liquid step by step. In an equal production scale, the batch number of cell dissociation is reduced, and the high-titer measles virus liquid is obtained, so that quality uniformity of measles-series vaccine products is improved effectively, and product yield is increased.

The present invention relates to a method for preparation of a swine pseudorabies virus vaccine, the method comprises the follwoing steps: (1) preparation of suspension passage cells; (2) multiplication culture of the suspension passage cells prepared by the step (1); and (3) inoculation of pseudorabies virus onto the suspension passage cells after the multiplication culture of the step (2), and multiplication culture of the pseudorabies virus. Compared with production methods in the prior art, production process is simplified, and cost is reduced. The swine pseudorabies virus vaccine can well avoid attacks from market popular highly pathogenic pseudorabies virus strains, and economic losses caused by pseudorabies can be reduced.

The invention provides a method for producing an avian influenza vaccine by using cells cultured by a spherical microcarrier bioreactor. The method comprises the following steps of: selecting seed cells; passaging cells reproduced in a spinner bottle; harvesting the cells in the spinner bottle; inoculating the cells; culturing the inoculated cells in the bioreactor; inoculating avian influenza virus; reproducing the avian influenza virus; collecting avian influenza virus liquid; inactivating the avian influenza virus liquid; preparing an avian influenza cell vaccine; and immunizing the avian influenza cell vaccine. By the method, the defects that the avian influenza vaccine produced by the traditional process is long in production period, large in inter-batch difference, high in endotoxin content and influenced by the supply of embryo eggs, and a tablet carrier is difficult to amplify are overcome; and the prepared avian influenza vaccine product is small in inter-batch difference, free from bacterial pollution, low in endotoxin content and formaldehyde content, stable in quality and short in the production period, and the tablet carrier is easy to amplify.

The present invention provides a method for producing a swine pseudorabies live vaccine by using a passage cell source, and a swine pseudorabies live vaccine product thereof. The method comprises: adopting passage cells to culture a swine pseudorabies virus attenuated strain; harvesting to obtain a cell culture virus solution; and adding a stabilizer, and carrying out freezing vacuum drying to obtain the passage cell derived swine pseudorabies live vaccine. During the use, the diluent of the prepared vaccine of the present invention can further be used. According to the present invention, the method has advantages of simple and stable production process, easy operation, high virus content, low difference between batches, controllable quality, significant vaccine yield and quality improving, and the like, the obtained product can be stored for a long time at the room temperature, especially at the temperature of 2-8 DEG C, the shelf life can be 36 months, and the diluted vaccine obtained by diluting the vaccine with the diluent of the present invention can be stored for a long time at the room temperature and can maintain the stability.

The invention discloses a CV-A10 virus species and an inactivated vaccine thereof for human. The classification name of the species is coxsackie virus A group 10-type with the preservation number being CGMCC No.16218; and the prepared CV-A10 inactivated vaccine for human consists of 100 [mu]g/ml of CV-A10 inactivated purified antigens and 1mg/ml of aluminium hydroxide. Results indicate that the vaccine products have favorable immunogen and safety.

The invention provides a purification method for split influenza virus vaccine. An influenza virus strain is inoculated onto a chick embryo and cultured to obtain a virus solution; the virus solution is sequentially subjected to inactivation and ultrafiltration concentration to obtain an ultrafiltrate; the obtained ultrafiltrate is subjected to cane sugar density gradient centrifugation by using a KII continuous flow centrifuge to obtain an ultra centrifugal solution; the ultra centrifugal solution is subjected to ultrafiltration dialysis for cane sugar removal and molecular sieve gel chromatography to obtain a virus purification solution; the obtained virus purification solution is subjected to virus split by using a split agent TritonX-100 and sodium deoxycholate; after the split is over, the split agent is removed via ultrafiltration dialysis; impure protein is centrifugally removed from the obtained split solution; supernatant is collected, filtered and sterilized so as to obtain the purified influenza virus vaccine primary solution. The purification method is simple and convenient to operate, high in centrifugation capacity and suitable for large-scale production; by adopting a dual-split agent and a centrifugal process, the finished product is greatly improved in activity (hemagglutinin content/protein total content), and approaches the activity ratio of subunit vaccine, as a result, the high-grade split influenza virus vaccine product is obtained.

The invention provides a method for detecting the content of D antigen in poliovirus type III and belongs to the technical field of antigen detection. Through matching of a poliovirus type III specific polyclonal antibody and a monoclonal antibody, the content of D antigen in poliovirus type III can be detected in a highly targeted mode without detecting C antigen. The method is easy to operate, the detection result can truly reflect the content of effective antigen in poliovirus, a basis can be well provided for follow-up poliomyelitis vaccine immunogenicity testing usage and the final concentration of a vaccine product, and the quality of poliomyelitis vaccine can be improved finally. The method has a high economic value and a high market application value.

The invention discloses a heat-resistant freezing and drying protecting agent for a contagious ovine ecthyma virus cell attenuated vaccine as well as a preparation method and application of the heat-resistant freezing and drying protecting agent. According to the characteristics of the contagious ovine ecthyma virus cell attenuated vaccine, the heat-resistant freezing and drying protecting agent for the contagious ovine ecthyma virus cell attenuated vaccine is prepared, wherein the heat-resistant freezing and drying protecting agent contains 30g/L-70g/L of trehalose, 10g/L-30g/L of skim milk powder, 10g/L-30g/L of polyvinylpyrrolidone, 5g/L-15g/L of gelatin, 0.5g/L-4g/L of arginine, 1g/L-5g/L of vitamin C, and the balance being of ultra-pure water. By virtue of the heat-resistant freezing and drying protecting agent disclosed by the invention, the vaccine can be stored for 24 months at 2 DEG C-8 DEG C while viral titer is not changed greatly; before and after freezing and drying a vaccine product, virus loss ratio is 0.3 titer, and the virus loss ratio is only 1.0 titer while the vaccine is stored for 30 days at 37 DEG C. According to the heat-resistant freezing and drying protecting agent disclosed by the invention, a bottleneck technology that the contagious ovine ecthyma virus cell attenuated vaccine only can be stored and transported at (-)15 DEG C is solved, so that the vaccine is more convenient to store and transport.